EXPERT OPINION ON BIOLOGICAL THERAPY, published by Taylor & Francis Ltd, is a prestigious journal that has been a cornerstone in the fields of Clinical Biochemistry, Drug Discovery, and Pharmacology since its inception in 2001. With an impressive impact factor reflecting Q1 status across its categories in 2023, this journal is ranked among the top in both the pharmacology and biochemistry domains, featuring in the 81st and 77th percentiles respectively. This makes it an essential resource for researchers, professionals, and students who are keen on staying at the forefront of biological therapy advancements. The journal encompasses a broad yet focused scope, providing valuable insights into innovative therapeutic strategies and drug development methodologies. Researchers benefit from the rigorous peer-review process and the opportunity to disseminate their findings to a global audience, without the constraints of open access, ensuring the integrity and prestige of published work. As it converges towards 2024, EXPERT OPINION ON BIOLOGICAL THERAPY remains an influential platform for fostering collaboration and discussion in the evolutionary landscape of biological therapies.

CNS DRUGS is a leading journal dedicated to the field of neuroscience, specifically focused on the advancement of pharmacological therapies for central nervous system disorders. Published by ADIS INT LTD, this esteemed journal has maintained a strong impact within its domain, achieving Q1 rankings in 2023 across multiple categories, including Neurology (clinical), Pharmacology (medical), and Psychiatry and Mental Health. With an impressive Scopus ranking as the 11th of 272 in medical pharmacology and high percentiles in psychiatry and neurology, it fosters high-quality research publication and dissemination. Spanning over two decades from 1994 to 2024, CNS DRUGS serves as a vital resource for researchers, professionals, and students alike, providing comprehensive insights that drive innovation in clinical practices. Although primarily a subscription-based journal, the richness of its content makes it an essential addition to any institution's library. Striving to bridge the gap between scientific research and clinical application, CNS DRUGS is positioned at the forefront of neurological and psychiatric pharmacotherapy research.

Pain and Therapy is a prestigious, peer-reviewed journal published by SPRINGER INTERNATIONAL PUBLISHING AG that has been a beacon of research in the field of pain management and neurology since its inception in 2012. With an ISSN of 2193-8237 and an E-ISSN of 2193-651X, this open access journal facilitates the dissemination of high-quality research to a global audience. Recognized within the top Q1 quartile for Anesthesiology and Pain Medicine, and the Q2 category for Clinical Neurology, it ranks impressively within the Scopus indexing, positioned at #20/136 in its primary category, demonstrating an 85th percentile standing. The journal's commitment to open access enhances its impact, allowing researchers, clinicians, and students to explore and contribute to critical developments in pain therapy and management. The convergence of cutting-edge research and innovative therapeutic strategies makes Pain and Therapy an essential resource for anyone dedicated to advancing knowledge in this vital field.

MEDICINAL RESEARCH REVIEWS, published by Wiley, is a leading journal in the fields of Drug Discovery, Molecular Medicine, and Pharmacology. With an impressive impact factor and esteemed standing in its category quartiles (Q1 in all three fields), this journal serves as a vital platform for the dissemination of cutting-edge research and reviews that drive innovation in therapeutic development and molecular health sciences. Since its inception in 1981, MEDICINAL RESEARCH REVIEWS has garnered a robust readership within the scientific community, underscored by its high rankings in Scopus – where it ranks #3 in Pharmacology and #2 in Drug Discovery, placing it within the top echelons of academic influence. Researchers, professionals, and students alike benefit from its rich content and comprehensive approaches to tackling complex medicinal challenges, making it an essential resource for those invested in advancing the frontiers of biomedical research.

Expert Opinion on Drug Metabolism & Toxicology, published by Taylor & Francis Ltd, is a leading journal in the fields of pharmacology and toxicology, with a distinguished reputation gleaned from its Q1 rankings in both disciplines as of 2023. With an ISSN of 1742-5255 and an E-ISSN of 1744-7607, this journal aims to foster innovative discussions and critical insights into the metabolism and toxicological assessment of drugs, appealing to a wide audience of researchers, professionals, and students. The journal's commitment to maintaining high academic standards is reflected in its placement within the top quartiles of the Scopus rankings—ranked 17th in Toxicology and 73rd in Pharmacology—demonstrating its significant impact and relevance in advancing knowledge within the drug development sector. Published since 2005 and converging into 2024, it provides a platform for timely dissemination of expert opinions, systematic reviews, and original research, reinforcing its vital role in shaping the future of pharmacological sciences in an ever-evolving landscape.

Pharmacy & Pharmacology-Farmatsiya i Farmakologiya is a distinguished journal published by the Pyatigorskii Mediko-Farmatsevticheskii Inst in the Russian Federation, dedicated to advancing research in the fields of pharmacy and pharmacology. Since its transition to an Open Access format in 2013, it has become an invaluable resource for researchers and professionals seeking to disseminate and access high-quality findings. With its ISSN 2307-9266 and E-ISSN 2413-2241, this journal covers a broad range of topics, providing a platform for the latest developments in pharmaceutical sciences. It is noteworthy that, as of 2023, Farmatsiya i Farmakologiya is categorized in various quartiles, with its Q2 ranking in Pharmacology (nursing) and Q3 in Pharmacy indicating its growing impact and relevance within its field. With the journal's commitment to fostering innovation and collaboration in pharmacy and pharmacology research, it serves as an essential hub for academics, practitioners, and students aiming to contribute to and stay informed about the dynamic landscape of this critical discipline.

CARDIOVASCULAR DRUGS AND THERAPY, published by Springer, is a premier journal dedicated to the latest advances in cardiovascular pharmacology and therapeutics. With a significant impact factor and esteemed rankings in cardiology and pharmacology, this journal is positioned in the top quartile categories, reflecting its influence and contribution to the field. Since its inception in 1987, the journal has served an international audience, providing a platform for researchers and practitioners to publish high-quality original research, critical reviews, and innovative clinical studies that address pressing issues in cardiovascular health. The journal's rigorous peer-review process ensures the utmost scholarly merit, making it an essential resource for professionals aiming to stay at the forefront of cardiovascular drug research and therapy. While not an open-access publication, it is widely available through institutional subscriptions, enhancing its reach within the global community of cardiology researchers and practitioners. Located in the Netherlands, CARDIOVASCULAR DRUGS AND THERAPY continues to play a vital role in advancing our understanding of cardiovascular diseases and the pharmacological solutions available to combat them.

Expert Review of Clinical Pharmacology, published by TAYLOR & FRANCIS LTD, is a leading peer-reviewed journal dedicated to the field of clinical pharmacology, with a strong focus on the development and application of pharmacological therapies in patient care. Boasting an impressive impact, the journal ranks in the first quartile across multiple categories including Medicine (miscellaneous), Pharmacology (medical), and Pharmacology, Toxicology and Pharmaceutics (miscellaneous), reflecting its influential position within the scientific community. With a Scopus ranking of #6 in General Pharmacology, Toxicology and Pharmaceutics, the journal also achieves a commendable 93rd percentile, further emphasizing its importance as a resource for researchers and clinicians alike. As it continues to publish innovative reviews and research articles from 2008 until 2024, the Expert Review of Clinical Pharmacology plays an essential role in advancing knowledge, improving clinical practice, and fostering collaboration among experts in pharmacology, thereby driving forward the field's evolution towards better patient outcomes.

Tropical Journal of Pharmaceutical Research is an esteemed open-access platform dedicated to advancing the field of pharmaceutical sciences, published by the Pharmacotherapy Group in Nigeria. With an ISSN of 1596-5996 and open access established since 2002, this journal serves as a critical resource for researchers, professionals, and students seeking to disseminate and access high-quality research in both pharmaceutical science and pharmacology. Despite its ranking in the third quartile (Q3) for Pharmaceutical Science and the fourth quartile (Q4) in Pharmacology as of 2023, the journal continues to stand out with its commitment to fostering significant dialogue and innovation in the scientific community. Anchored at the University of Benin, Faculty of Pharmacy, the journal invites contributions that explore novel pharmaceutical research, clinical applications, and drug development, playing a vital role in addressing health challenges that are particularly relevant to tropical regions. Researchers can look forward to publishing their findings in a journal that not only promotes the sharing of knowledge but also enhances the scientific discourse within a rapidly evolving field.

INVESTIGATIONAL NEW DRUGS is a prestigious journal published by SPRINGER, dedicated to advancing research in the fields of pharmacology and oncology. With its origins dating back to 1983, the journal continues to play a critical role in disseminating groundbreaking studies and innovative methodologies related to drug development and therapeutic strategies. It holds an impressive impact factor among leading academic publications, ranking in the top quartiles (Q1 and Q2) of its respective categories, evidenced by Scopus rankings of #43/272 in Medical Pharmacology and #88/404 in Medical Oncology. While it offers traditional subscription-based access, it remains an essential resource for researchers, professionals, and students eager to stay abreast of significant advancements in drug research. Through rigorous peer review and comprehensive coverage, INVESTIGATIONAL NEW DRUGS aims to foster the development of effective new therapies and enhance our understanding of pharmacological interventions in oncology.